SCLC Clinical Trials 2024

What are the top hospitals conducting sclc research?

When it comes to cutting-edge clinical trials in the realm of small cell lung cancer (SCLC), several top hospitals are leading the charge. Memorial Sloan Kettering Cancer Center, located in New york City, is at the forefront with seven active SCLC trials and a total of 23 completed trials dedicated to this aggressive form of lung cancer. Since their first recorded trial in 2007, they have been committed to pushing boundaries and seeking innovative treatment options for patients. Washington University School of Medicine in Saint Louis also deserves recognition, boasting six ongoing SCLC trials and an impressive record of 24 previous trials dating back to their inaugural study in 1992.

Meanwhile, down south at Moffitt Cancer Center in Tampa, researchers are making significant strides as well. With six active SCLC trials and 18 past studies under their belt since initiating their first trial on this condition back in 2008, they demonstrate dedication towards improving patient outcomes. PCR Oncology based in Arroyo Grande may be smaller-scale comparatively but plays a vital role with six current SCLC clinical trials; although they have only conducted five all-time investigations since recording its maiden trial on sclc cases In2007 proving every effort made towards understanding this disease is valuable.

Lastly yet importantly,the Lewis Cancer and Research Pavilion at Saint Joseph's/Candler situatedin Savannah seeks contribution through conducting six ongoing tests which adds over previous nine held experiments tracingback ten years ago till when it started participating from year2008 into such widespread medical research.The efforts by these top hospitals indicate not only progress but hope for those affected by small cell lung cancer worldwide.Through each trial conducted we edge closer toward unravelling mysteries surrounding treatments which ensure brighter future for countless patients suffering from this deadly condition

Which are the best cities for sclc clinical trials?

When it comes to small cell lung cancer (SCLC) clinical trials, several cities stand out as key players in research and development. Anchorage, Alaska leads the pack with 28 active trials focusing on promising treatments such as Pembrolizumab, Erlotinib Hydrochloride, and Cisplatin. Following closely behind is Los Angeles, California with 27 ongoing studies investigating similar interventions like Pembrolizumab and Erlotinib Hydrochloride. Houston, Texas also plays a significant role in SCLC research with 25 active trials exploring innovative approaches such as Local Consolidation Therapy and the NovoTTF-200M device. These cities offer individuals diagnosed with SCLC access to cutting-edge clinical trials that may pave the way for improved treatment options and outcomes.

Which are the top treatments for sclc being explored in clinical trials?

In the realm of small cell lung cancer (SCLC) research, several treatments are currently under investigation in clinical trials. Leading the pack is pembrolizumab, a formidable contender with 10 ongoing trials and a history of 26 all-time SCLC trials since its debut in 2014. Another noteworthy player is durvalumab, making waves with three active trials and an impressive track record of 33 all-time SCLC trials since its introduction in 2016. Additionally, stereotactic radiosurgery has emerged as a newcomer on the scene, showing promise with two active trials and three total SCLC trials recorded since its first listing in 2020. As researchers delve deeper into these potential breakthroughs, new avenues for treating SCLC continue to emerge on the horizon.

What are the most recent clinical trials for sclc?

Promising advancements in the field of small cell lung cancer (SCLC) treatment have emerged through recent clinical trials. One notable trial investigates the efficacy of cemiplimab, a novel therapeutic approach for SCLC patients. This Phase 2 study offers hope for improved outcomes and enhanced quality of life. Additionally, ongoing research focuses on dose-finding strategies in non-small cell lung cancer (NSCLC), aiming to adapt them to benefit individuals with SCLC as well. Furthermore, DB-1311 has shown potential as a treatment option through its dual-phase investigation encompassing both Phase 1 and Phase 2 trials. Another experimental drug, LB2102, is currently being evaluated in a Phase 1 trial for its effectiveness against SCLC. Tocilizumab also presents promise as it undergoes combined Phase 1 and Phase 2 testing towards developing innovative treatment options for this aggressive form of lung cancer. These groundbreaking studies mark significant steps forward in the fight against SCLC and offer renewed optimism to those affected by this disease.

What sclc clinical trials were recently completed?

Several notable clinical trials evaluating treatments for small cell lung cancer (SCLC) have recently concluded, offering valuable insights into potential therapeutic options. In July 2021, BeiGene's trial investigating the effectiveness of Ociperlimab concluded successfully. Another significant trial was completed in March 2021 by EMD Serono Research & Development Institute, Inc., examining the efficacy of Berzosertib. These recent advancements contribute to our understanding and bring hope to patients battling SCLC.